Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer

Clinical Cancer Research

Volumn 20, Issue 16, 2014, Pages 4240-4250

  Van Cutsem, Eric ^a   Eng, Cathy ^b   Nowara, Elzbieta ^f   Swieboda Sadlej, Anna ^g   Tebbutt, Niall C ^h   Mitchell, Edith ^c   Davidenko, Irina ⁱ   Stephenson, Joe ^d   Elez, Elena ^j   Prenen, Hans ^a   Deng, Hongjie ^e   Tang, Rui ^e   McCaffery, Ian ^e,l   Oliner, Kelly S ^e   Chen, Lisa ^e   Gansert, Jennifer ^e   Loh, Elwyn ^e   Smethurst, Dominic ^k   Tabernero, Josep ^j  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d Cancer Centers of the Carolinas   (United States)

^e AMGEN INC   (United States)

^f INSTITUTE OF ONCOLOGY   (Poland)

^g MEDICAL UNIVERSITY OF WARSAW   (Poland)

^h AUSTIN HEALTH   (Australia)

ⁱ Krasnodar City Oncology Center   (Russian Federation)

^j VALL D HEBRON UNIVERSITY HOSPITAL   (Spain)

^k AMGEN LTD   (United Kingdom)

^l GENENTECH INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GANITUMAB; PANITUMUMAB; PLACEBO; RILOTUMUMAB; SCATTER FACTOR RECEPTOR; SOMATOMEDIN; TUMOR MARKER; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; MONOCLONAL ANTIBODY; ONCOPROTEIN; RAS PROTEIN;

ABDOMINAL PAIN; ACNEIFORM DERMATITIS; ADULT; ADVERSE OUTCOME; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EPISTAXIS; FATIGUE; FEMALE; HUMAN; HYPOMAGNESEMIA; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MONOTHERAPY; NAUSEA; ONCOGENE K RAS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PARONYCHIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SKIN DISEASE; SKIN FISSURE; TREATMENT RESPONSE; VOMITING; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; FOLLOW UP; GENETICS; LIVER NEOPLASMS; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SURVIVAL RATE; YOUNG ADULT;

EID: 84905968151     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2752     Document Type: Article

References (28)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008:GLOBOCAN2008. Int J Cancer 2010;127:2893-917.
2. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. Wild-type KRAS is required for panitumumab effi cacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26: 1626-34.
3. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28:4697-705.
4. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:4706-13.
5. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64. (Pubitemid 46797944)
6. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341 -54.
7. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000;275:8806-11. (Pubitemid 30180235)
8. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43. (Pubitemid 46799492)
9. Lesko E, Majka M. The biological role of HGF-MET axis in tumor growth and development of metastasis. Front Biosci 2008;13:1271-80. (Pubitemid 351594710)
10. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48.
11. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4: 915 - 25.
12. Kammula US, Kuntz EJ, Francone TD, Zeng Z, Shia J, Landmann RG, et al. Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007;248:219-28. (Pubitemid 46330555)
13. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, Hamilton SR, et al. Gene expression pro files in normal and cancer cells. Science 1997;276:1268-72. (Pubitemid 27227367)
14. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen JG, Weiser MR. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011;17:472-82.
15. Ahmad T, Farnie G, Bundred NJ, Anderson NG. The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem 2004;279:1713-9. (Pubitemid 38084438)
16. Roudabush FL, Pierce KL, Maudsley S, Khan KD, Luttrell LM. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phosphorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 2000;275:22583-9. (Pubitemid 30621851)
17. Swantek JL, Baserga R. Prolonged activation of ERK2 by epidermal growth factor and other growth factors requires a functional insulin-like growth factor 1 receptor. Endocrinology 1999;140:3163-9. (Pubitemid 30650632)
18. Sarantopoulos J, Mita AC, Mulay M, Romero O, Lu J, Capilla F, et al. A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) orgemcitabine (G). J Clin Oncol 2008 (suppl 15; abstr 3583);26.
19. Hecht JR, Mitchell E, Neubauer MA, Burris HA 3rd, Swanson P, Lopez T, et al. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 2010;16:2205-13.
20. Mao C, Liao RY, Chen Q. Loss of PTEN expression predicts resistance to EGFR-targeted monoclonal antibodies in patients with metastatic colorectal cancer. Br J Cancer 2010;102:940.
21. Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, et al. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer 2012;11:143-50.
22. Reidy DL, Vakiani E, Fakih MG, Saif MW, Hecht JR, Goodman-Davis N, et al. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. J Clin Oncol 2010;28:4240-6.
23. Garofalo C, Manara MC, Nicoletti G, Marino MT, Lollini PL, Astolfi A, et al. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011;30:2730- 40.
24. Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, et al. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther 2011;337:644-54.
25. Zeng ZS, Weiser MR, Kuntz E, Chen CT, Khan SA, Forslund A, et al. c-Met gene ampli fication is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008;265: 258 - 69.
26. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, et al. Overexpression and amplifi cation of the met/HGF receptor gene during the progression of colorectal cancer. Clin Cancer Res 1995; 1:147-54.
27. Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, et al. Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013;3:658- 73.
28. Davidenko I, Iveson T, Donehower RC, Tjulandin S, Deptala A, Jiang Y, et al. Updated efficacy, biomarker, and exposure-response data from a phase 2 study of rilotumumab (R) plus epirubicin, cisplatin, and capecitabine (ECX) in gastric (G) or esophagogastric junction (EGJ) cancer. Annals of Oncology 2012 (suppl 9; abstr P687);ix230.